Skip to main content
OpenTrials
Recruiting

NCT Number: NCT06455813

What Laxative Should be Used After Hip Fracture Surgery?

To conduct a randomized clinical trial to determine how best to prevent constipation after hip fracture surgery using laxatives.

Recruiting

Interested in participating?

Request Info

Key information

Age range

65 year–110 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 4

Primary location

Hospital Lillebælt, Kolding Hospital, Kolding, Denmark

Loading trial locations.

About this study

Background:

Acute constipation is very common in connection with major operations. Constipation is a complication that can prolong hospital stays, increase nursing time and healthcare costs. Up to 70% experience constipation after surgery for a hip fracture. Prevention of constipation is considered an important part of treatment after hip surgery, but although the use of anti-constipation drugs is widespread, there are no studies of sufficient quality to show how and with what means constipation is best treated. For the same reason, in Denmark there is great variation in the approach to preventive treatment - and thus also the treatment result.

Aim:

The aim is to investigate how to prevent constipation best after hip surgery using laxatives.

Method, design, intervention og investigation procedures:

The project is a randomized controlled trial in ratio 1:1:1, where the patients assigned to two different orthopedic surgery departments are assigned to either have one of two drugs (bisacodyl, macrogol) or both types of anti-constipation drugs. It is calculated that 375 patients will be included in the trial, i.e. 125 patients in each group. It is expected that patients will be evenly included distributed between two hospitals.

The patients will respectively be given macrogol 3350 and electrolytes (ATC code A06AD65) which is administered as the content of 2 sachets, Bisacodyl (ATC code A06AB02) 5 mg, 2 tablets or a combination of both in half the dose.

All laxatives are administered orally in the evening on the day of surgery (the next standard administration time at 10 pm) and it is known to both patients and staff which trial medication each patient is receiving. The patients' stool frequency, degree of constipation and side effects of the medication as well as pain, nausea and flatulence are scored once a day using the Bristol Stool Scale, Verbal Rank Scale and Patient Assessment of Constipation symptoms Questionnaire. If the first defecation has not occurred 72 hours after the end of the operation, the patients in all three groups are transferred to treatment with peristalsis-promoting agents Bisacodyl 5 mg, 2 tablets. The patients stay in the trial and get the trial medication they are assigned to unless an orthopedic surgeon assesses otherwise.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Acute hip fracture surgery patients from one of two orthopedic departments from hospitals in the Southern Region of Denmark.
  • Age≥ 65 years
  • The patients should be able to speak and understand Danish.

Exclusion criteria

  • Patients:
  • with known chronic constipation (defined from Wexner constipation score)
  • with known use of laxatives at admission
  • who participate in other similar clinical studies
  • who is terminally ill
  • who is restraint
  • who is in isolation
  • with severe heart disease defined as New York Heart Association (NYHA) III og IV
  • with severe chronically inflammatory bowel disease
  • with acute abdominal surgical conditions, eg. ileus, obstruction or perforation
  • with dysphagia where the patient can not swallow tablets/oral liquids
  • with toxic megacolon
  • with gastric emptying disorder
  • with severe electrolyte disorder (P-kalium: < 2.5 mmol/l og P-natrium: <125 mmol/l)
  • Allergies to the ingredients
  • Pregnant women can not be included but the women are expected to be postmenopausal why pregnancy test are not performed

Treatment and study plan

Bisacodyl

Drug

The patients' stool frequency, degree of constipation and side effects of the medication as well as pain, nausea and flatulence are scored once a day using the Bristol Stool Scale, Verbal Rank Scale and Patient Assessment of Constipation symptoms Questionnaire. If the first defecation has not occurred 72 hours after the end of the operation, the patients in all three groups are transferred to treatment with peristaltic-promoting agents

Other names: Dulcolax

Macrogol 3350 and electrolytes

Drug

The patients' stool frequency, degree of constipation and side effects of the medication as well as pain, nausea and flatulence are scored once a day using the Bristol Stool Scale, Verbal Rank Scale and Patient Assessment of Constipation symptoms Questionnaire. If the first defecation has not occurred 72 hours after the end of the operation, the patients in all three groups are transferred to treatment with peristaltic-promoting agents

Other names: Gangiden

A combination of macrogol 3350 and electrolytes and bisacodyl

Drug

The patients' stool frequency, degree of constipation and side effects of the medication as well as pain, nausea and flatulence are scored once a day using the Bristol Stool Scale, Verbal Rank Scale and Patient Assessment of Constipation symptoms Questionnaire. If the first defecation has not occurred 72 hours after the end of the operation, the patients in all three groups are transferred to treatment with peristaltic-promoting agents

Other names: A combination of Gangiden og Dulcolax

Primary outcomes

  1. The proportion of patients who will need rescue medication (Bisacodyl)

    Time frame: 72 hours after surgery

    Part of patients in each group who needs rescue medication after 72 hours or rescue medication before 72 hours on behalf of a medical assessment

Secondary outcomes

  1. Time to first bowel movements

    Time frame: hours up to 240 hours

    Time to first bowel movements (in hours after finished surgery)

  2. Length of hospital stay

    Time frame: days up to 10 days

    Length of hospital stay of the index admission from admission to discharge

  3. Number of patients who are readmitted at hospital

    Time frame: 30 days

    The part of patients who are readmitted at hospital 30 days after discharge hospital

  4. Number of patients who have emergency room visits

    Time frame: 30 days

    The proportion of patients who have emergency room visits within 30 days of discharge hospital

  5. Constipation defined from the Bristol Stool Scale

    Time frame: daily up to 10 days

    constipation defined from the Bristol Stool Scale with type 1-7 where type 1 is constipation and type 7 is diarrhea and use/no use of rescue medication (bisacodyl)

  6. Constipation score

    Time frame: daily up to 10 days

    Calculated score based of The Patient Assessment of Constipation symptoms Questionnaire from 0-48 where 48 is most severe constipation and use/no use of rescue medication (bisacodyl)

Study contacts

Contact information is provided by the study sponsor or research team.

Anton Pottegård

CONTACT

[email protected]

0045 28913340

Carina Lundby

CONTACT

[email protected]

Sponsors and collaborators

Lead sponsor

Odense University Hospital

Other

Collaborators

  • Independent Research Fund Denmark

Registry information

Official study title

Oral Laxatives After Hip Fracture Surgery: A Randomised Controlled Trial

Important dates

Study start
2024
Primary completion
2027
Study completion
2027
First posted
Jun 12, 2024
Registry last updated
Jul 31, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.